



GITANJALI SARAF

Designation: Senior Partner

Gitanjali.Sarafesarafpartners.com

Expertise: Corporate Law; Technology Law; Sports Law; Environment Law; Not for Profit Regime.

Education: LL. B., University of Delhi

Bar Admission: Bar Council of Delhi

Awards and Recognitions:

- Recognised amongst 'Top Female Lawyers in India 2023' by Asian Legal Business;
- Inducted in the Hall of Fame: Legacy Builders of Law by BW Legal World's 100
 Most Influential Women 2023;
- Recognised as an honorary member by International Who's Who Historical Society.

Overview: Gitanjali Saraf is a Senior Partner at Saraf and Partners. Her expertise lies in corporate law, technology law, sports law, environment law and not for profit regime.

With experience on both sides of the spectrum, as an external legal consultant and a General Counsel, Gitanjali brings a well-rounded expertise to the table. Her role as the General Counsel involved heading the Legal and Secretarial Department of the Indian subsidiaries of Perot Systems Corporation, USA—a Fortune 1000 Corporation. Gitanjali's sphere of responsibilities extended beyond the Indian company to encompass 20 subsidiaries across North America, Europe, Middle East, and the Asia Pacific region, including prominent locations such as Japan, Hong Kong, China, and the Philippines. Furthermore, she was extended a board position within the company.

Gitanjali has been honoured by the International Who's Who Society for her exemplary accomplishments and distinguished service. Moreover, Gitanjali was featured in BW Legal World's prestigious "100 Most Influential Women 2023" list, specifically recognized as a "Legacy Builder of Law." This esteemed list acknowledges 100 women leaders who are driving change and progress in the Indian legal ecosystem.

Gitanjali is a Mentor on Digital Mentorship Platform for Women which is a global mentorship e-platform to promote women's leadership at all levels through knowledge exchange.



The portal is hosted on the women's empowerment platform of NITI Aayog and serves as a global mentoring and capacity-building portal for women mentees and mentors from G-20 nations.

Experience: An illustrative list of key deals handled by Gitanjali is as below:

- Capgemini: Acted for and advised Capgemini in relation to its acquisition of Nasdaq-listed technology and services company iGATE Corporation. The deal involved several critical India-specific issues on account of substantial presence of iGATE in India and the Firm advised on Indian corporate, competition and tax issues and other aspects of the transaction. The transaction is valued at USD 4 billion.
- Advised *Viatris Inc.* and its Indian subsidiary, Mylan Pharmaceutical Private Limited ("Mylan India") in the acquisition of the India piece of the Upjohn Business from Pfizer's Indian subsidiaries. Pursuant to the global combination, Upjohn Inc., a subsidiary of Pfizer Inc., housing Pfizer's global Upjohn Business (primarily off-patent branded and generic established medicines business) combined with Mylan N.V., in a US\$ 12 billion deal, leading to creation of a new global pharmaceutical company, i.e., Viatris Inc.
- Advised *Hitachi* on its US\$ 6.4 billion acquisition of the world-leading Power Grids business from Swiss engineering group ABB Ltd. Hitachi has entered into agreement with ABB, for Hitachi to initially acquire 80.1% stake in the Power Grids, with an option to acquire the remaining 19.9% stake at a later stage.
- Vedanta Group in relation to joint venture with Foxconn to establish India's first semiconductor fab in Gujarat. This is one of the biggest pathbreaking joint venture deal with outlay of US\$ 20 billion. It is a first of its kind landmark transaction to set up India's first semiconductor fab facility under the Government of India's Fab Scheme. Biggest innovative part of the deal was to create right type of contractual framework so that a minority partner (Foxconn) is able to transfer technology for semiconductor to Joint Venture (which is controlled by Vedanta Group) which required enormous negotiation and structuring.
- Advised Viatris to sell its global biosimilars assets to Biocon Biologics Limited ("BBL"), subsidiary of Biocon Limited for US\$ 3.335 billion for stock and cash consideration. Viatris (formally called as 'Mylan') is a global healthcare company, listed on NASDAQ. This deal is the largest M&A deal in the world in biosimilars business and one of the largest M&A deals in India in pharmaceutical space.